CATALYST is a Phase III clinical study evaluating the safety and efficacy of bardoxolone methyl (an oral medication) for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH). This includes PAH associated with lupus, scleroderma, Sjögren’s syndrome, rheumatoid arthritis, and other connective tissue diseases. Approximately 200 patients will be enrolled at centers in various countries around the world.

See if you prequalify